Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03423342 · ClinicalTrials.gov registry record · Phase 1
Nicotinamide Riboside in Systolic Heart Failure
A Phase 1 study, sponsored by University of Washington.
- Completed
- Registry status
- Phase 1
- Development phase
- 30
- Enrollment target
NCT03423342 is a Phase 1 study that has completed, run by University of Washington. The registered enrollment target is 30 participants.
The verdict
NCT03423342, a Phase 1 study, has completed, sponsored by University of Washington.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 30 participants
- Enrollment target
Study Summary
Mitochondrial dysfunction has been implicated in heart failure (HF), and is associated with an imbalance in intracellular ratio of reduced nicotinamide-adenine dinucleotide (NADH) to oxidized nicotinamide-adenine dinucleotide (NAD), or the NADH/NAD ratio. In mouse models of HF, we have found that normalization of the NADH/NAD, through supplementation with NAD+ precursors, is associated with improvement in cardiac function. This Study will randomize participants with systolic HF (ejection fraction ≤40%) to treatment with the NAD precursor, nicotinamide riboside (NR) or matching placebo, uptitrated to a final oral dose of 1000mg twice daily, to determine the safety and tolerability of NR in participants with systolic HF.
Interventions
- DRUG Placebo
- DIETARY_SUPPLEMENT nicotinamide riboside
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2016-05-19 |
| Est. Completion | 2019-06-30 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03423342
The ClinicalTrials.gov registry entry for NCT03423342 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Washington, which has 1,048 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT03423342 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03423342 about?
NCT03423342 is a clinical study titled "Nicotinamide Riboside in Systolic Heart Failure". Mitochondrial dysfunction has been implicated in heart failure (HF), and is associated with an imbalance in intracellular ratio of reduced nicotinamide-adenine dinucleotide (NADH) to oxidized nicotinamide-adenine dinucleotide (NAD), or the NADH/NAD ratio. In mouse models of HF, we have found that no...
What is the current status of trial NCT03423342?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 30 participants. The study started on 2016-05-19. Estimated completion is 2019-06-30.
What interventions are being tested in trial NCT03423342?
The interventions under investigation include: Placebo (DRUG), nicotinamide riboside (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT03423342?
This trial is sponsored by University of Washington, which has 1,048 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.